Amarantus Releases Preliminary Data From Blood-Based MS Diagnostic

Amarantus BioScience has released preliminary data from a blood test for multiple sclerosis (MS) called the MSPrecise diagnostic. The company believes that the test could lead to more accurate diagnoses of MS early in the disease’s progression. MSPrecise is a DNA sequencing test designed to identify specific DNA mutations that are associated with the immune system, and more specifically, a type of immune system […]

Read more

Rich Yu talks about how incubator saving water during CA drought

Rich Yu talks about how incubator saving water during CA drought Richard Yu, Ph.D., scientific and operations director for the QB3@953 incubator in San Francisco, told GEN his facility is also heeding the need for water conservation. “I flagged a person for using cold running water to cool an eletrophoresis gel and begged them to use a recirculating water chiller, […]

Read more

SolveBio, MedGenome Ink Data Distribution Agreement

Today, SolveBio, a provider of data infrastructure for genomics, announced a partnership with San Francisco, Calif.-based MedGenome to distribute MedGenome’s OncoMD proprietary cancer mutation knowledgebase through its platform. With this agreement, SolveBio users will now have programmatic access to the OncoMD content using the company’s application programming interface, open source language bindings, and visual interfaces. Researchers, tumor sequencing panel developers, […]

Read more

4D Molecular Therapeutics Partners with Roche on Gene Therapy Vectors

4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development, today announced a collaboration and license agreement with Roche to discover and develop optimized next-generation AAV vectors for indications with high unmet medical need. 4DMT will deploy its proprietary AAV vector discovery platform, Directed Vector Evolution, to identify and optimize novel gene delivery vectors for […]

Read more

Amarantus Bio Raises $5M

Amarantus BioScience Holdings today said that it closed on a $5 million investment from privately held mutual fund Discover Growth Fund. Amarantus plans to use the financing to further develop and commercialize its neurology diagnostic products and therapeutic drug candidates, and for other working capital expenses, it said. In conjunction with the investment, the San Francisco-based company issued a new […]

Read more

Nerd Stalker gets the QB3 pitch

Nerd Stalker gets the QB3 pitch Greg Viloria of the Silicon Valley blog Nerd Stalker interviewed Kaspar Mossman, QB3 communications and marketing director, recently at QB3@953. Greg generously allowed Kaspar to explain the entire spectrum of how QB3 helps Bay Area entrepreneurs start life science companies–Startup in a Box, incubators, the venture fund Mission Bay Capital. Plus, a little about […]

Read more

Helen Lam converts Alector internship into research associate position

Helen Lam converts Alector internship into research associate position During her internship at biotech startup Alector, Helen Lam learned for the first time the advantages that scientists gain by working in a team. She also got a career boost. Helen now works full-time as a research associate at Alector, which develops antibody therapies for Alzheimer’s and other forms of dementia. […]

Read more

Ethan Perlstein featured in Science Careers

Ethan Perlstein featured in Science Careers Ethan Perlstein never planned to be a CEO. Ever since his college research internship in a lab at the National Institutes of Health (NIH), he had dreamed of becoming a professor at a high-powered research institution. After completing his Ph.D. in molecular and cellular biology at Harvard and earning a Lewis-Sigler fellowship at Princeton, […]

Read more

Privail Wins the Vator Splash Health 2015 People’s Choice Award

At Vator Splash Health, Privail won the People’s Choice Award. Here’s the video of Anwaar Al-Zireeni, Privail co-founder and CEO, giving on of the winning presentation. Privail is developing point-of-care diagnostics for the early detection of infectious diseases, with an initial focus on HIV. Unlike current diagnostic methods, Privail’s test detects the virus itself and is available in a simple, […]

Read more

Encoded Genomics, Xcell Bio among those to benefit from Illumina Accelerator’s $40M

Illumina today announced that its startup accelerator has secured $40 million from Viking Global Investors to fund promising genomic firms. Accelerator graduates that raise between $1 million and $5 million in new capital will receive additional dollar-for-dollar match funding from Illumina Accelerator Boost Capital. Read more at GenomeWeb

Read more
Page 8 of 10« First...678910

Upcoming Event

  • Office Hours with WSGR Patent and Corporate Law

    To apply for Office Hours contact: Carol Ochoa Sponsored by:
    Ali Alemozafar Dr. Ali R. Alemozafar is a senior associate at Wilson Sonsini Goodrich & Rosati, where he focuses on patent prosecution, strategic patent counseling, and IP due diligence in a wide range of technical fields, including diagnostics, therapeutics, genomics, and materials. Ali received his Ph.D. in chemical engineering at Stanford University, where he investigated the reactivity and atomic-scale changes accompanying reactions on various catalysts. During his postdoctoral research fellowship at the Department of Chemistry and Chemical Biology at Harvard University, he investigated the dynamics of TiOx nanoparticles and the use of gold as an oxidation catalyst. Prior to attending law school, Ali worked on data warehousing, business intelligence, and enterprise data integration. Ali frequently lectures at the UC Berkeley School of Law and UC Hastings College of the Law on various intellectual property topics, including patent strategy and IP due diligence. Michael Hostetler Dr. Mike Hostetler is a partner in the SOMA and San Diego offices of Wilson Sonsini Goodrich & Rosati, where he provides strategic intellectual property counseling to more than 100 growth enterprises in the pharmaceutical and biotechnology, and information technology industries. He works with both venture-backed and public companies. His expertise includes patent strategy, patent prosecution, and patent diligence (both buy and sell side) for venture financings, public offerings, and mergers and acquisitions. He has provided patent counseling in support of pharmaceutical and biotechnology, and information technology products in all stages of development, from proof of concept to regulatory approval to product launch. He leads a talented team of patent associates and patent agents that can meet virtually any technical and strategic need. Mike currently serves as a member of the firm's Policy and Nominating Committees. Elton Satusky Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. He specializes in public and private corporate finance and corporate law and governance. Elton also has considerable expertise in the areas of mergers and acquisitions and venture capital.


953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287

Sign-Up for our Newsletter